Humana (NYSE:HUM) Price Target Lowered to $158.00 at The Goldman Sachs Group

Humana (NYSE:HUM) had its price objective reduced by stock analysts at The Goldman Sachs Group from $215.00 to $158.00 in a research note issued to investors on Friday,MarketScreener reports. The brokerage presently has a “sell” rating on the insurance provider’s stock. The Goldman Sachs Group’s price objective indicates a potential downside of 14.09% from the stock’s current price.

A number of other equities analysts have also issued reports on HUM. JPMorgan Chase & Co. decreased their price objective on Humana from $274.00 to $180.00 and set a “neutral” rating for the company in a report on Friday. Leerink Partners reduced their price target on Humana from $267.00 to $185.00 and set a “market perform” rating for the company in a research report on Thursday. Robert W. Baird decreased their price target on Humana from $280.00 to $264.00 and set a “neutral” rating for the company in a research note on Thursday, December 11th. Royal Bank Of Canada cut shares of Humana from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $322.00 to $189.00 in a research note on Thursday. Finally, Truist Financial reduced their price objective on shares of Humana from $300.00 to $285.00 and set a “hold” rating for the company in a report on Monday, November 10th. Seven analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $238.29.

Humana Stock Performance

HUM stock opened at $183.92 on Friday. Humana has a 1 year low of $169.61 and a 1 year high of $315.35. The stock has a market capitalization of $22.12 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 1.99 and a beta of 0.44. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.02 and a current ratio of 2.00. The stock’s fifty day moving average is $244.65 and its two-hundred day moving average is $260.85.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, topping the consensus estimate of ($4.01) by $0.05. The business had revenue of $32.64 billion during the quarter, compared to analyst estimates of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The company’s quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, research analysts predict that Humana will post 16.47 EPS for the current year.

Institutional Investors Weigh In On Humana

Several hedge funds and other institutional investors have recently bought and sold shares of HUM. Montag A & Associates Inc. grew its stake in shares of Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after purchasing an additional 94 shares during the last quarter. CoreCap Advisors LLC boosted its holdings in Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Fideuram Asset Management Ireland dac acquired a new position in Humana in the fourth quarter worth approximately $27,000. Rosenberg Matthew Hamilton grew its position in Humana by 136.0% in the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after buying an additional 68 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Humana in the second quarter valued at $32,000. 92.38% of the stock is currently owned by institutional investors.

More Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.